Carbocyclic sulfonamides

ABSTRACT

(1) Prostaglandin (PG) E 2  antagonist or agonist containing carbocyclic sulfonamides represented by the compound of the formula (I): ##STR1## cyclodextrin clathrates thereof, non-toxic salts thereof as active ingredient, (2) carbocyclic sulfonamides represented by the compound of the formula (II): ##STR2## cyclodextrin clathrates thereof, non-toxic salts thereof, (3) process for the preparation of the compound represented by the compound of the formula (II) described hereinbefore, (4) PGE 2  antagonist or agonist containing the compound represented by the compound of the formula (II) as active ingredient. 
     The compounds represented by the compounds of the formula (I) and (II) can be adapted to medicines which possess an inhibitory effect of uterine contraction, an analgetic action, an inhibitory effect of digestive peristalsis, a sleep-inducing effect as PGE 2  antagonists, and an uterine contractile activity, a promoting effect of digestive peristalsis, a suppressive effect of gastric acid secretion, a hypotensive activity as PGE 2  agonists, because they bind onto PGE 2  receptor and have an activity of antagonist or agonist against the action thereof.

SUMMARY

This invention is related to carbocyclic sulfonamides. Moreparticularly, this invention is related to:

(1) prostaglandin E₂ antagonists or agonists which comprises carbocyclicsulfonamides of the formula: ##STR3## wherein all the symbols are thesame meaning as hereafter defined, as active ingredient,

(2)-1 carbocyclic sulfonamides of the formula: ##STR4## wherein all thesymbols are the same meaning as hereafter defined, (2)-2 prostaglandinE₂ antagonists or agonists which comprises carbocyclic sulfonamides ofthe formula (Iy) as active ingredient and

(2)-3 process for the preparation of carbocyclic sulfonamides of theformula (Iy).

BACKGROUND

As prostaglandin (PG)E₂ agonists, many compounds have been knownincluding PGE₂ per se or its derivatives. However, no compounds whichantagonize for PGE₂ or inhibit PGE₂ activity have been known until now.

PGE₂ has been known as a metabolite in the arachidonate cascade. It hasbeen known that PGE₂ has uterine contractile activity, a pain-inducingeffect, a promoting effect of digestive peristalsis, an awaking effect,a suppressive effect of gastric acid secretion, a hypotensive activityetc.

To antagonize PGE₂ means to suppress the effects above mentioned, soPGE₂ antagonists are considered to inhibit uterine contraction, to havean analgetic action, to inhibit digestive peristalsis, to induce sleep.Therefor, PGE₂ antagonists are considered to be useful for analgesics,antidiarrheals, sleep inducer or for the preventive of abortion.

To agonize for PGE₂ means to promote the effects above mentioned, soPGE₂ agonists are considered to have a uterine contractile activity, topromote digestive peristalsis, to suppress gastric acid secretion, tolower blood pressure. Therefor, PGE₂ agonists are considered to beuseful for abortient, cathartics, antiulcer, anti-gastritis,antihypertensive.

RELATED ARTS

The compound of the formula (Ix) used in the present invention wasdisclosed to be useful for thromboxane A₂ (TxA₂) antagonists in thespecification of the U.S. Pat. No. 5,168,101 and the U.S. Pat. No.4,861,913.

These specifications disclose the following each compounds.

That is, the specification of the U.S. Pat. No. 5,168,101 disclosessulfonamide compounds of the formula: ##STR5## wherein R^(1a) is i)COOR^(11a),

ii) CH₂ OR^(12a) or

iii) CONR^(13a) R^(14a)

in which R^(11a) is hydrogen, C1-20 alkyl, carbocyclic ringunsubstituted or substituted by C1-4 alkyl, alkoxy or halogen, orsteroid;

R^(12a) is hydrogen or COR^(15a) ;

R^(13a) and R^(14a) each, independently, is hydrogen, C1-4 alkyl or

NR^(13a) R^(14a) is amino acid residue or heterocyclic ring;

R^(15a) is C1-4 alkyl or phenyl; ##STR6## Baa is i) --CH₂ --CH₂(CH₂)_(ma) -- (Baa-1),

ii) cis--CH═CH--(CH₂)_(ma) -- (Baa-2),

iii) --CH₂ --O--(CH₂)_(ma) -- (Baa-3),

iv) --S--(CH₂)_(ma) -- (Baa-4) or

v) ##STR7## in which ma is 1-6, a double bond is E, Z and EZ mixture andphenylene is o-, m- or p-phenylene in the formula (Baa-5);

R^(2aa) is a single bond or C1-4 alkylene;

R^(3aa) is carbocyclic ring or heterocyclic ring unsubstituted orsubstituted by one to three of C1-4 alkyl, C1-4 alkoxy, hydroxy,carboxyl, cyano, halogen or nitro or

R^(2aa) and R^(3aa) taken together, is C1-12 alkyl; ##STR8## Xba is i) asingle bond,

ii) C1-4 alkylene or

iii) C2-4 alkenylene,

with the proviso that, .sup.α CH═CHCH₂.sup.β and .sup.α CH₂CH═CHCH₂.sup.β are excluded;

R^(2ba) is

i) hydrogen,

ii) halogen or

iii) C1-4 alkyl;

the configuration of a double bond between C5-C6 in the formula (Ba) iscis; ##STR9## Lca is C1-4 alkylene; R^(2ca) is hydrogen, C1-4 alkyl orhalogen;

the configuration of a double bond between C5-C6 in the formula (Ca) iscis or trans;

with the proviso that, when ##STR10## is the formula (Aa), R^(11a) isnot hydrogen and C1-20 alkyl; cyclodextrin clathrates thereof andnon-toxic acid salts thereof, when R^(11a) is hydrogen or NR^(13a)R^(14a) is amino acid residue.

The specification of the U.S. Pat. No. 4,861,913 disclosesbicyclosulfonamide derivatives of the formula: ##STR11## wherein R^(1b)is hydrogen or lower alkyl (C1-8); R^(2b) is alkyl, aryl or substitutedaryl, aralkyl or heterocyclic ring;

R^(3b) is hydrogen or methyl;

Xb is alkylene or alkenylene which may be substituted fluorine orcontained oxygen, sulfur and/or phenylene in the chain;

Yb is straight or branched alkylene or alkenylene, oxygen or sulfur;

mb is 0 or 1;

nb is 0, 1 or 2;

and salts thereof.

Further, Bayer AG published the following compound in InternationalSymposium on the chemistry of Natural Products at from May, 29 to Jun.3, 1988. ##STR12##

COMPARISON WITH THE RELATED ARTS

As mentioned above, the compounds of the formula (Ix), except for a partthereof, are overlapped with those of the formulae (a), (b) and (c)described in related arts.

However, the compounds Of the formula (a), (b) and (c) are disclosedonly to be useful for TXA₂ antagonist. The disclosure does not suggestthe use as PGE₂ antagonists or agonists which is made clear in thepresent invention.

TXA₂ has been known to have activities of platelet aggregation, aortacontraction, thrombi formation, etc., and therefore, TXA₂ antagonist isconsidered to be useful for antiinflammatory agents, antithromboticagents, treatment of cardiac infraction.

Meanwhile, as mentioned above PGE₂ has been known to have an uterinecontractile activity, a pain-inducing effect, a promoting effect ofdigestive peristalsis, an awaking effect, a suppressive effect ofgastric acid secretion, a hypotensive activity etc. Therefor, PGE₂antagonists are considered to inhibit uterine contraction, to have ananalgetic action, to inhibit digestive peristalsis, to induce sleep, andPGE₂ agonists are considered to have uterine contractile activity, topromote digestive peristalsis, to suppress gastric acid secretion, toblood pressure.

As understood from the above fact, PGE₂ antagonist or agonist differsfrom TXA₂ antagonist in active site, mechanism, application and propertythereof. So it is difficult to expect that compounds have both actionsat the same time.

The compounds of the formula (Iy) of the present invention differ fromthose of the formulae (a), (b) and (c) in the structure and thepharmacological action thereof. So the compound of the formula (Iy) cannot be expected easily from these compounds.

That is, in the structural view point, all the compounds of the formula(Iy) have a double bond between a sulfonamide group (NR⁴⁰⁰ --SO₂) andthe end of ω-chain (R⁵⁰⁰). The compounds differ from the compounds ofthe formulae (a), (b) and (c) in this point.

In the pharmacological view point, PGE₂ antagonism or PGE₂ agonism hasnothing to do with TXA₂ antagonism. Therefore, PGE₂ antagonism or PGE₂agonism of the compound of the formula (Iy) can not be expected fromTXA₂ antagonism of the compound of the formulae (a), (b) and (c). Thereis no suggestion in any of the related arts mentioned above that PGE₂antagonism or PGE₂ agonism is maintained even though a double bond isintroduced in ω-chain.

DISCLOSURE OF THE INVENTION

The present invention is related to a novel use of known compounds,novel compounds, process for the preparation of the novel compounds anda use of the novel compounds.

Accordingly, the present invention is related to

(1) prostaglandin E₂ antagonists or PGE₂ agonists which comprisescarbocyclic sulfonamides of the formula: ##STR13## wherein R¹ is i)COOR¹¹ or

ii) CONR¹³ R¹⁴

in which R¹¹ is hydrogen, C1-20 alkyl;

R¹³ and R¹⁴ each, independently, is hydrogen, C1-4 alkyl or

NR¹³ R¹⁴ is amino acid residue; ##STR14## Ba is i) --CH₂ --CH₂ (CH₂)_(m)-- (Ba-1) or

ii) cis--CH═CH--(CH₂)_(m) -- (Ba-2)

in which m is 1-6;

R^(2a) is a single bond or C1-4 alkylene;

R^(3a) is benzene, naphthalene or C4-7 cycloalkyl unsubstituted orsubstituted by one to three of C1-4 alkyl, C1-4 alkoxy, hydroxy, cyano,halogen, trifluoromethyl or nitro or

R^(2a) and R^(3a) taken together, is C1-12 alkyl; ##STR15## Xb is i) asingle bond,

ii) C1-4 alkylene or

iii) C2-4 alkenylene,

with the proviso that, .sup.α CH═CHCH₂.sup.β and .sup.α CH₂CH═CHCH₂.sup.β are excluded;

R^(2b) is hydrogen, C1-4 alkyl, C1-4 alkoxy, hydroxy, cyano, halogen,trifluoromethyl or nitro;

the configuration of a double bond between C5-C6 in the formula (B) iscis; ##STR16## Lc is C1-4 alkylene; R^(2C) is hydrogen, C1-4 alkyl, C1-4alkoxy, hydroxy, cyano, halogen, trifluoromethyl or nitro;

the configuration of a double bond between C5-C6 in the formula (c) iscis or trans;

cyclodextrin clathrates thereof or non-toxic acid salts thereof, whenR¹¹ is hydrogen or NR¹³ R¹⁴ is amino acid residue, as active ingredient,

(2)-1 carbocyclic sulfonamides of the formula: ##STR17## R¹⁰⁰ is C4-7alkylene or C4-7 alkenylene; R²⁰⁰ is hydroxy, C1-20 alkoxy or NR²³⁰ R²⁴⁰in which R²³⁰ and R²⁴⁰ each, independently, is hydrogen, C1-4 alkyl orNR²³⁰ R²⁴⁰ is amino acid residue;

R³⁰⁰ is a single bond or C1-4 alkylene;

R⁴⁰⁰ is hydrogen or C1-4 alkyl;

R⁵⁰⁰ and R⁹⁰⁰ each, independently, is ##STR18## in which R⁶⁰⁰ ishydrogen, C1-4 alkyl, C1-4 alkoxy, hydroxy, halogen, trifluoromethyl,nitro;

nn is 1, 2 or 3; ##STR19## in which R⁶¹⁰ is hydrogen, C1-4 alkyl, C1-4alkoxy, hydroxy, halogen, trifluoromethyl, nitro;

mm is 1, 2 or 3; ##STR20## in which R⁶²⁰ is hydrogen, C1-4 alkyl, C1-4alkoxy, hydroxy, halogen, trifluoromethyl, nitro;

kk is 1, 2 or 3;

pp is 3, 4, 5, or 6;

iv) C1-7 alkyl or

v) hydrogen;

cyclodextrin clathrates thereof or non-toxic salts thereof,

(2)-2 process for the preparation of the compounds of the formula (Iy)and

(2)-3 prostaglandin E₂ antagonists or agonists which comprises thecompounds of the formula (Iy) as active ingredient.

The terms of alkyl, alkylene, alkenylene and alkoxy in description ofeach symbol throughout the present specification including claims meanstraight-chain or branched-chain alkyl, alkylene, alkenylene and alkoxy.The configuration of double bonds in alkenylene are E, Z and E, Zmixtures.

The presence of asymmetric centers leads, as is well known, to theexistence of isomers. And all optical isomers and all mixtures thereofare included in the formula (Ix) and (Iy). For instance, a mixture ofone optical isomer and enantiomer thereof, a racemate which is anequivalent mixture especially and a mixture of one optical isomer anddiastereomer thereof are also included.

In the structural formula throughout the present specification dottedline ##STR21## indicate α-configuration, tapered line ##STR22## indicateβ-configuration.

In the formula (Ix) and (Iy), for example, the ring structures of theformula: ##STR23## is named each and numbered at each position asfollows. ##STR24##

As will be apparent to those skilled in the art, the ring structuresdescribed above have two [in case of the formula (Aa-4), (Aa-6) and(Aa-7)] or four [in case of the formula (Aa-1), (Aa-2), (Aa-3) and(Aa-5)] asymmetric carbons. Namely, they are 1-, 2-, 3- and 4-positioncarbons in the formula (Aa-1) and (Aa-3), 1-, 4-, 5- and 6-positioncarbons in the formula (Aa-2), 2- and 3-position carbons in the formulae(Aa-4), 1- and 2-position carbons in the formula (Aa-6) and (Aa-7) and1-, 2-, 3- and 5-position carbons in the formula (Aa-5).

And, in the formula (Ix) and (Iy), the ring structures of the formula:##STR25## is named each and numbered at each position as follows.##STR26##

As will be apparent to those skilled in the art, the ring structuresdescribed above have asymmetric carbons. Namely, the ring structures ofthe formula (Ab-1) and (Ab-2) have two asymmetric carbons (1- and3-position carbons), and the ring structures of the formula (Ab-3) and(Ab-4) have four asymmetric carbons (1-, 2-, 4- and 6-position carbons).

And, in the formula (Ix), the ring structures of the formula: ##STR27##is named each and numbered at each position as follows. ##STR28##

As will be apparent to those skilled in the art, the ring structuresdescribed above have two [in case of the formula (Ac-2), (Ac-3), (Ac-6)and (Ac-7)] or four [in case of the formula (Ac-1), (Ac-4), (Ac-5) and(Ac-8)] asymmetric carbons. Namely, they are 2- and 3-position carbonsin the formula (Ac-2), 1- and 2-position carbons in the formula (Ac-3)and (Ac-7), 1- and 6-position carbons in the formula (Ac-6), 1-, 2-, 3-and 4-position carbons in the formula (Ac-1) and (Ac-8), 1-, 4-, 5- and6-position carbons in the formula (Ac-4) and (Ac-5).

The steric structures of each isomers or racemates are shown by absoluteconfiguration, for example, as follows.

(i) in case of an optically active substance ##STR29## amide of(5Z)-7-[(1S,2S,3S,5R)-3-phenylsulfonylamino-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid and glycine ##STR30## amide of(5Z)-7-[(1R,2S,3S,4S)-3-phenylsulfonylaminobicyclo[2.2.1]heptan-2-yl]hept-5-enoicacid and glycine ##STR31##(5Z)-6-[(1R,3S)-3-phenylsulfonylaminocyclopentyl]hex-5-enoic acid##STR32##(5Z)-7-[(1R,2R,4R,6S)-6-phenylsulfonylaminobicyclo[2.2.1]heptan-2-yl]hept-5-enoicacid

(ii) in case of racemate ##STR33## amide of(5Z)-7-[(2S*,3S*)-3-phenylsulfonylaminobicyclo[2.2.2]octan-2-yl]hept-5-enoicacid and glycine ##STR34##(5Z,7E)-8-[(1S*,3S*)-3-phenylsulfonylaminocyclohexyl]oct-5,7-dienoicacid

In the formula (Ix), C1-20 alkyl represented by R¹¹ means methyl, ethyl,propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl,dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl,octadecyl, nonadecyl, icosyl and isomeric groups thereof. Preferable R¹¹are methyl, ethyl, propyl, isopropyl, 1-ethylpropyl, hexyl, octyl,decyl, dodecyl. It's also preferable that R¹¹ is hydrogen.

In the formula (Ix), C1-4 alkyl represented by R¹³ and R¹⁴ means methyl,ethyl, propyl, butyl and isomeric groups thereof.

In the formula (Ix), amino acid residues represented by NR¹³ R¹⁴ meanα-amino acid residues wherein a hydrogen in the amino is removed. Forexample, they are glycine, alanine, valine, isoleucine, leucine, serine,threonine, proline, asparagine, glutamine, methionine, phenylalanine,tyrosine, aspartic acid, glutamic acid or lysine residue. Preferableamino acid residue are glycine, alanine, glutamic acid, lysine residue.

Preferable the ring structure of the formula: ##STR35## is bridged ringsrepresented by the formula (Aa-1), (Aa-4), (Aa-5), (Aa-6) and (Aa-7).

In the formula (Ix), out of groups represented by Ba, the formula (Ba-2)having a double bond is preferred.

In the formula (Ix), the formula --(CH₂)_(m) -- means methylene,ethylene, trimethylene, tetramethylene, pentamethylene andhexamethylene, and preferable group is trimethylene.

In the formula (Ix), R^(2a) means a single bond or C1-4 alkyl. C1-4alkyl means methyl, ethyl, propyl, butyl and isomeric groups thereof.Preferable R^(2a) is a single bond.

In the formula (Ix), C4-7 cycloalkyl represented by R^(3a) meanscyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl.

In the formula (Ix), C1-4 alkyl represented by substituents in R^(3a)means methyl, ethyl, propyl, butyl and isomeric groups thereof, C1-4alkoxy means methoxy, ethoxy, propoxy, butoxy and isomeric groupsthereof, and halogen means fluorine, chlorine, iodine and bromine.

In the formula (Ix), C1-12 alkyl represented by R^(2a) and R^(3a) takentogether means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl,octyl, nonyl, decyl, undecyl, dodecyl and isomeric groups thereof, andall groups are preferable.

All the rings represented by the formula: ##STR36## are preferable.

In the formula (Ix), C1-4 alkylene represented by Xb means methylene,ethylene, trimethylene, tetramethylene and isomeric groups thereof.

In the formula (Ix), C2-4 alkenylene represented by Xb means vinylene,propenylene, butenylene, butadienylene and isomeric groups thereof.

Preferable Xb is a single bond, methylene, ethylene and vinylene.Especially preferable group is a single bond.

In the formula (Ix), C1-4 alkyl represented by R^(2b) means methyl,ethyl, propyl, butyl and isomeric groups thereof, C1-4 alkoxyrepresented by R^(2b) means methoxy, ethoxy, propoxy, butoxy andisomeric groups thereof, and halogen means fluorine, chlorine, iodineand bromine and all groups are preferable. It's also preferable thatR^(2b) is hydrogen.

Preferable the ring structure of the formula: ##STR37## is the groupsrepresented by the formula (Ac-1), (Ac-3), (Ac-4) and (Ac-7).

In the formula (Ix), C1-4 alkylene represented by LC means methylene,ethylene, trimethylene and tetramethylene, and preferable groups aremethylene and ethylene.

In the formula (Ix), C1-4 alkyl represented by R^(2c) means methyl,ethyl, propyl, butyl and isometric groups thereof, and preferable groupsis methyl. C1-4 alkoxy represented by R^(2c) means methoxy, ethoxy,propoxy, butoxy and isomeric groups thereof. Halogen represented byR^(2c) means fluorine, chlorine, bromine and iodine and preferable groupis bromine.

In the formula (Iy), C4-7 alkylene represented by R¹⁰⁰ meanstetramethylene, pentamethylene, hexamethylene, heptamethylene andisomeric groups thereof.

In the formula (Iy), C4-7 alkenylene represented by R¹⁰⁰ meansbutenylene, pentenylene, hexenylene, heptenylene and isomeric groupsthereof.

Preferable R¹⁰⁰ is pentamethylene, hexamethylene, pentenylene andhexenylene.

In the formula (Iy), C1-20 alkoxy represented by R²⁰⁰ means methoxy,ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy,nonyloxy, decyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy,pentadecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy, nonadecyloxy,icosyloxy and isomeric groups thereof.

In the formula (Iy), C1-4 alkyl represented by R²³⁰ and R²⁴⁰ meansmethyl, ethyl, propyl, butyl and isomeric groups thereof.

In the formula (Iy), amino acid residues represented by NR²³⁰ N²⁴⁰ meanα-amino acid residues wherein a hydrogen in the amino is removed. Forexample, they are glycine, alanine, valine, isoleucine, leucine, serine,threonine, proline, asparagine, glutamine, methionine, phenylalanine,tyrosine, aspartic acid, glutamic acid or lysine residue.

In the formula (Iy), C1-4 alkylene represented by R³⁰⁰ means methylene,ethylene, trimethylene, tetramethylene and isomeric groups thereof.

Preferable R³⁰⁰ is a single bond and methylene.

In the formula (Iy), C1-4 alkyl represented by R⁴⁰⁰ means methyl, ethyl,propyl, butyl and isomeric groups thereof.

Preferable R⁴⁰⁰ is hydrogen and methyl.

In the formula (Iy), C1-4 alkyl represented by R⁶⁰⁰, R⁶¹⁰ and R⁶²⁰ meansmethyl, ethyl, propyl, butyl and isomeric groups thereof.

In the formula (Iy), C1-4 alkoxy represented by R⁶⁰⁰, R⁶¹⁰ and R⁶²⁰means methoxy, ethoxy, propoxy, butoxy and isomeric groups thereof.

In the formula (Iy), halogen represented by R⁶⁰⁰, R⁶¹⁰ and R⁶²⁰ meansfluorine, chlorine, bromine and iodine.

Preferable R⁶⁰⁰, R⁶¹⁰ and R⁶²⁰ are hydrogen, fluorine, chlorine,bromine, iodine, methyl, methoxy, nitro and trifluoromethyl.

In the formula (Iy), the formula: ##STR38## means cyclobutyl,cyclopentyl, cyclohexyl and cycloheptyl, and preferable group iscyclohexyl.

In the formula (Iy), C1-7 alkyl represented by R⁵⁰⁰ and R⁹⁰⁰ meansmethyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and isomeric groupsthereof.

Preferable Compounds

In the compounds of the present invention of the formula (Ix), thecompounds described in Example and the following compounds arepreferable.

7-[3-(2-Naphtyl)sulfonylaminobicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-(2-Cyclohexylethyl)sulfonylaminobicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-Hexylsulfonylaminobicyclo[2.2.1]heptan-2-yl]-5-heptenoic acid,

7-[5-(4-Methylphenyl)sulfonylaminobicyclo[2.2.1]-2-heptan-6-yl]-5-heptenoicacid,

7-[5-(2-Naphtyl)sulfonylaminobicyclo[2.2.1]-2-heptan-6-yl]-5-heptenoicacid,

7-[5-(2-Cyclohexylethyl)sulfonylaminobicyclo[2.2.1]-2-heptan-6-yl]-5-heptenoicacid,

7-[5-Hexylsulfonylaminobicyclo[2.2.1]-2-heptan-6-yl]-5-heptenoic acid,

7-[3-(4-Methylphenyl)sulfonylamino-7-oxa-bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-(2-Naphtyl)sulfonylamino-7-oxa-bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-(2-Cyclohexylethylsulfonylamino)-7-oxa-bicyclo[2.2.1]heptan-2-yl]-5-heptenoic acid,

7-[3-Hexylsulfonylamino-7-oxa-bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-(2-Naphtyl)sulfonylaminobicyclo[2.2.2]octan-2-yl]-5-heptenoic acid,

7-[3-(2-Cyclohexylethyl)sulfonylaminobicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-Hexylsulfonylaminobicyclo[2.2.2]octan-2-yl]-5-heptenoic acid,

7-[3-(4-Methylphenyl)sulfonylamino-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5-heptenoicacid,

7-[2-(4-Methylphenyl)sulfonylaminocyclohexyl]-5-heptenoic acid,

7-[2-(2-Naphtyl)sulfonylaminocyclohexyl]-5-heptenoic acid,

7-[2-(2-Cyclohexylethyl)sulfonylaminocyclohexyl]-5-heptenoic acid,

7-[2-Hexylsulfonylaminocyclohexyl]-5-heptenoic acid,

7-[2-(2-Naphtyl)sulfonylaminocyclohexyl]-5-heptenoic acid,

7-[2-(2-Cyclohexylethyl)sulfonylaminocyclopentyl]-5-heptenoic acid,

7-[2-Hexylsulfonylaminocyclopentyl]-5-heptenoic acid,

6-[3-(4-Methylphenyl)sulfonylaminocyclopentyl]-5-hexenoic acid,

7-[3-(4-Methylphenyl)sulfonylaminocyclopentyl]-5-heptenoic acid,

8-[3-(4-Methylphenyl)sulfonylaminocyclopentyl]-5,7-octadienoic acid,

6-[3-(4-Methylphenyl)sulfonylaminocyclohexyl]-5-hexenoic acid,

7-[3-(4-Methylphenyl)sulfonylaminocyclohexyl]-5-heptenoic acid,

8-[3-(4-Methylphenyl)sulfonylaminocyclohexyl]-5,7-octadienoic acid,

6-[6-(4-Methylphenyl)sulfonylaminobicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

7-[6-(4-Methylphenyl)sulfonylaminobicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

8-[6-(4-Methylphenyl)sulfonylaminobicyclo[2.2.1]heptan-2-yl]-5,7-octadienoicacid,

6-[6-(4-Methylphenyl)sulfonylaminobicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

7-[6-(4-Methylphenyl)sulfonylaminobicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

8-[6-(4-Methylphenyl)sulfonylaminobicyclo[2.2.2]octan-2-yl]-5,7-octadienoicacid,

6-[3-(4-Methylphenyl)sulfonylaminomethylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-(4-Methylphenyl)sulfonylaminomethylbicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[2-(4-Methylphenyl)sulfonylaminomethylcyclohexyl]-5-hexenoic acid,

6-[5-(4-Methylphenyl)sulfonylaminomethylbicyclo[2.2.1]-2-hepten-6-yl]-5-hexenoicacid,

6-[5-(4-Methylphenyl)sulfonylaminomethylbicyclo[2.2.2]-2-octen-6-yl]-5-hexenoicacid,

6-[6-(4-Methylphenyl)sulfonylaminomethyl-3-cyclohexenyl]-5-hexenoicacid,

6-[2-(4-Methylphenyl)sulfonylaminomethylcyclopentyl]-5-hexenoic acid,

6-[3-(4-Methylphenyl)sulfonylaminomethyl-7-oxa-bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

and ester, amido, amido with amino acid thereof.

In the compounds of the present invention of the formula (Iy), thecompounds described in the Examples and the following compounds arepreferable.

Esters, amides amides with amino acid of example compounds,

7-[3-[2-(4-Fluorophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan2-yl]-5-heptenoicacid,

7-[3-[2-(3-Fluorophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan2-yl]-5-heptenoicacid,

7-[3-[2-(4-Chlorophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Chlorophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Bromophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Bromophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Iodophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Iodophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Methylphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Methylphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Nitrophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Nitrophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Methoxyphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Methoxyphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(2,2-diphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

6-[3-[2-(4-Fluorophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(3-Fluorophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(4-Chlorophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(3-Chlorophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(4-Bromophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(3-Bromophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(4-Iodophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(3-Iodophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(4-Methylphenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(3-Methylphenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(4-Nitrophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(3-Nitrophenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(4-Methoxyphenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(3-Methoxyphenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[3-[2-(2,2-diphenyl)vinylsulfonylamino]metylbicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

7-[2-[2-(4-Fluorophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(3-Fluorophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(4-Chlorophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(3-Chlorophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(4-Bromophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(3-Bromophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(4-Iodophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(3-Iodophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(4-Methylphenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(3-Methylphenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(4-Nitrophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(3-Nitrophenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

7-[2-[2-(4-Methoxyphenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoicacid,

7-[2-[2-(3-Methoxyphenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoicacid,

7-[2-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoicacid,

7-[2-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoicacid,

7-[2-[2-(2,2-diphenyl)vinylsulfonylamino]cyclohexyl]-5-heptenoic acid,

6-[3-[2-(4-Fluorophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(3-Fluorophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(4-Chlorophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(3-Chlorophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(4-Bromophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(3-Bromophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(4-Iodophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(3-Iodophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(4-Methylphenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(3-Methylphenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(4-Nitrophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(3-Nitrophenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(4-Methoxyphenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(3-Methoxyphenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoicacid,

6-[3-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoicacid,

6-[3-[2-(2,2-diphenyl)vinylsulfonylamino]cyclohexyl]-5-hexenoic acid,

6-[3-[2-(4-Fluorophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid.

6-[3-[2-(3-Fluorophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(4-Chlorophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(3-Chlorophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(4-Bromophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(3-Bromophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(4-Iodophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(3-Iodophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(4-Methylphenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(3-Methylphenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(4-Nitrophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(3-Nitrophenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

6-[3-[2-(4-Methoxyphenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoicacid,

6-[3-[2-(3-Methoxyphenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoicacid,

6-[3-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoicacid,

6-[3-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoicacid,

6-[3-[2-(2,2-diphenyl)vinylsulfonylamino]cyclopentyl]-5-hexenoic acid,

7-[3-(2-phenylvinylsulfonylamino)bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Fluorophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Fluorophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Chlorophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Chlorophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Bromophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Bromophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Iodophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Iodophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Methylphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Methylphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Nitrophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Nitrophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Methoxyphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Methoxyphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[3-[2-(2,2-diphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-heptenoicacid,

7-[5-(2-phenylvinylsulfonylamino)-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(4-Fluorophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(3-Fluorophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(4-Chlorophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(3-Chlorophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(4-Bromophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(3-Bromophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(4-Iodophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(3-Iodophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(4-Methylphenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(3-Methylphenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(4-Nitrophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(3-Nitrophenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(4-Methoxyphenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(3-Methoxyphenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[5-[2-(2,2-diphenyl)vinylsulfonylamino]-2-bicyclo[2.2.1]hepten-6-yl]-5-heptenoicacid,

7-[3-(2-phenylvinylsulfonylamino)-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Fluorophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Fluorophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Chlorophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Chlorophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Bromophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Bromophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Iodophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Iodophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Methylphenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Methylphenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Nitrophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Nitrophenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Methoxyphenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Methoxyphenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[3-[2-(2,2-diphenyl)vinylsulfonylamino]-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoicacid,

7-[2-(2-phenylvinylsulfonylamino)cyclopentyl]-5-heptenoic acid,

7-[2-[2-(4-Fluorophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(3-Fluorophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(4-Chlorophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(3-Chlorophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(4-Bromophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoic acid,

7-[2-[2-(3-Bromophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoic acid,

7-[2-[2-(4-Iodophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoic acid,

7-[2-[2-(3-Iodophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoic acid,

7-[2-[2-(4-Methylphenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(3-Methylphenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(4-Nitrophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoic acid,

7-[2-[2-(3-Nitrophenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoic acid,

7-[2-[2-(4-Methoxyphenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(3-Methoxyphenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoicacid,

7-[2-[2-(2,2-diphenyl)vinylsulfonylamino]cyclopentyl]-5-heptenoic acid,

6-[6-(2-phenylvinylsulfonylamino)bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Fluorophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Fluorophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Chlorophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Chlorophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Bromophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Bromophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Iodophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Iodophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Methylphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Methylphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Nitrophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid.

6-[6-[2-(3-Nitrophenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid.

6-[6-[2-(4-Methoxyphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid.

6-[6-[2-(3-Methoxyphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-[2-(2,2-diphenyl)vinylsulfonylamino]bicyclo[2.2.1]heptan-2-yl]-5-hexenoicacid,

6-[6-(2-phenylvinylsulfonylamino)bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Fluorophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Fluorophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Chlorophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Chlorophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Bromophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Bromophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Iodophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Iodophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Methylphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Methylphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Nitrophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Nitrophenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Methoxyphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(4-Trifluoromethylphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(3-Trifluoromethylphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

6-[6-[2-(2,2-diphenyl)vinylsulfonylamino]bicyclo[2.2.2]octan-2-yl]-5-hexenoicacid,

and ester, amido, amido with amino acid thereof.

The ester compounds, amide compounds and amide compounds with aminoacid, themselves, have only week pharmacological activites, but theyshow strong activities when an ester and amide bonds thereof are brokenin the body after administration of them. They are what is called aprodrug.

Cyclodextrin Clathrates

The cyclodextrin clathrates of the compounds of the formula (Ix) and(Iy) of the present invention may be prepared by the method described inthe specification of the British Patent No. 1351238 or the BritishPatent No. 1419221, using α, β or γ-cyclodextrins or a mixture thereof.

By converting into cyclodextrin clathrates, the stability of thecompounds of the formula (Ix) and (Iy) can be increased.

Salts

The compounds which R¹¹ is hydrogen or NR¹³ R¹⁴ is amino acid residueamong the compounds of the formula (Ix), or R²⁰⁰ is hydroxy or NR²³⁰R²⁴⁰ is amino acid residue among the compounds of the formula (Iy), ofthe present invention may be converted into the corresponding salts.Non-toxic and water-soluble salts are preferable. Suitable salts, forexample, are follows:

salts of alkaline metal (sodium, potassium etc.), salts of alkalineearth metal (calcium, magnesium etc.), ammonium salts, salts ofpharmaceutically acceptable organic amine (tetramethylammonium,triethylamine, methylamine, dimethylamine, cyclopentylamine,benzylamine, phenethylamine, piperidine, monoethanolamine,diethanolamine, tris(hydroxymethyl)aminomethane, lysine, arginine,N-methyl-D-glucamine etc.).

Process for the Preparation

1) The compounds of the formula (Ix) are disclosed in the specificationof the U.S. Pat. No. 5,168,101 and the U.S. Pat. No. 4,861,913, and thedetailed processes for the preparation thereof are also disclosedtherein.

The structures of unspecified compounds are described with physical datain example described hereafter in the present specification.

The compounds in which R^(3a) is benzene, naphthalene or C4-7 cycloalkylsubstituted by trifluoromethyl, and in which R^(2b) or R^(2c) is C1-4alkoxy, hydroxy, cyano, nitro or trifluoromethyl, in the compounds ofthe formula (Ix), may be also prepared by the same method as mentionedabove.

2) The compounds of the formula (Iy) may be prepared as follows.

The compounds wherein R²⁰⁰ is R²⁰¹ in which R²⁰¹ is C1-20 alkoxy orNR²³⁰ R²⁴⁰ (wherein all the symbols are the same meaning as hereinbeforedefined), in the compounds of the formula (Iy), of the formula:##STR39## wherein all the symbols are the same meaning as hereinbeforedefined, may be prepared from those of the formula: ##STR40## whereinR⁵¹⁰ and R⁹¹⁰ each, independently, is ##STR41## in which R⁶⁰¹ ishydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl, nitro or2-tetrahydropyranyloxy;

nn is the same meaning as hereinbefore defined; ##STR42## in which R⁶¹¹is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl, nitro or2-tetrahydropyranyloxy;

mm is the same meaning as hereinbefore defined; ##STR43## in which R⁶²¹is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl, nitro or2-tetrahydropyranyloxy;

kk and pp are the same meaning as hereinbefore defined;

iv) C1-7 alkyl or

v) hydrogen,

and the other symbols are the same meaning as hereinbefore defined; bythe esterification reaction or the reaction of forming amide-bond, andby the hydrolysis in an acidic condition when R⁶⁰¹, R⁶¹¹ and R⁶²¹ is2-tetrahydropyranyloxy.

The esterification reaction is known, for example, it may be carried outusing (i) diazoalkane, (ii) a condensing agent (e.g.dicyclohexylcarbodiimide, Mukaiyama reagent etc.)

The method using diazoalkane of (i) is known, for example, it may becarried out using the corresponding diazoalkane, in an inert organicsolvent (e.g. tetrahydrofuran (THF), dioxan, ether, acetone etc.) at-10° C.˜40° C.

The method using a esterification agent of (ii) is known, for example,it may be carried out in an corresponding alkanol, using a condensingagent (dicyclohexylcarbodiimide, Mukaiyama reagent etc.) and tertiaryamine (e.g. triethylamine etc.) at -10° C.˜40° C.

The reaction to forming amide-bond is known, for example, it may becarried out (i) with using a corresponding amine of the formula HNR²³⁰R²⁴⁰ wherein R²³⁰ and R²⁴⁰ are the same meaning as hereinbefore defined,in an inert organic solvent (e.g. methylene chloride, toluene etc.) at0° C.˜40° C., after reacting oxalyl chloride, or (ii) with using acorresponding amine, Mukaiyama reagent and tertiary amine (e.g.triethylamine etc.), in an inert organic solvent (e.g. methylenechloride etc.), at 0° C.˜40° C. In case that an amine of the formulaHNR²³⁰ R²⁴⁰ is amino acid, the reaction is carried out by reacting thecompounds in which carboxyl in an amino acid is protected by appropriatealkyl, or the compounds in which an amino having no connection to thereaction is protected by tert-butoxycarbonyl (boc) or benzyloxy carbonyl(cbz), and then hydrolyzing with using an acid (trifuruoroacetic acidetc.) or an alkali (sodium hydroxide etc.) to remove a protecting group.

The hydrolysis of ester in an acidic condition is known, for example, itmay be carried out in water-miscible organic solvent (e.g. methanol,ethanol, THF, dioxan etc.), using an organic acid (e.g. acetic acid,p-toluenesulfonic acid, trichloroacetic acid etc.) or an inorganic acid(e.g. hydrochloride, sulfate, hydrobromide etc.) at 0° C.˜90° C.

The compounds which R²⁰⁰ is hydroxy in the compounds of the formula(Iy), of the formula: ##STR44## wherein all the symbols are the samemeaning as hereinbefore defined; may be prepared from those of theformula: ##STR45## wherein R⁷⁰¹ is C1-4 alkyl and the other symbols arethe same meaning as hereinbefore defined;

by the hydrolysis in an alkaline condition, and by the hydrolysis in anacidic condition when R⁶⁰¹, R⁶¹¹ and R⁶²¹ is 2-tetrahydropyranyloxy.

The hydrolysis of ester in an alkaline condition is known, for example,it may be carried out in a water-miscible organic solvent (e.g. THF,methanol, ethanol dimethoxyethane or mixture thereof etc.), using analkali (e.g. sodium hydroxide, potassium hydroxide etc.), at -10°C.˜100° C.

The hydrolysis of ester in an acidic condition may be carried out thesame procedure as mentioned above.

Besides, the procedure of this two reactions may be carried outreversibly.

The compounds of the formula (II) may be prepared from those of theformula (III) by the hydrolysis in an alkaline condition.

The hydrolysis of ester in an alkaline condition may be carried out thesame procedure as mentioned above.

The compounds of the formula (III) may be prepared by using a reactiondepicted in following Scheme (A).

The reaction step in parenthesis may be carried out, if desired.

The symbols in scheme is the following meaning or the same meaning ashereinbefore defined.

    ______________________________________                                        THP:           2-tetrahydropyranyl,                                           R.sup.101 :    a single bond or C1-4 alkylene,                                R.sup.102 :    C1-5 alkylene,                                                 R.sup.810 :    t-butoxycarbonyl,                                              R.sup.401 :    C1-4 alkyl,                                                    X.sup.10 :     halogen,                                                       X.sup.20 :     halogen,                                                       X.sup.30 :     halogen,                                                       X.sup.40 :     halogen,                                                       φ:         phenyl                                                         TsOH:          p-toluenesulfonic acid                                         ______________________________________                                         ##STR46##

In the formula (Iy), the compounds in which R¹⁰⁰ is C4-7 alkenylene,R²⁰⁰ is hydroxy, R⁵⁰⁰ is R⁵⁰¹, wherein R⁵⁰¹ is ##STR47## in which R⁶⁰²is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl or nitro,nn is the same meaning as hereinbefore defined, or ##STR48## in whichR⁶¹² is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl ornitro, mm is the same meaning as hereinbefore defined, or ##STR49## inwhich R⁶²² is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen,trifluoromethyl or nitro, kk and pp are the same meaning as hereinbeforedefined, or

iv) C1-7 alkyl and R⁹⁰⁰ is hydrogen;

of the formula: ##STR50## wherein all the symbols are the same meaningas hereinbefore defined; may be prepared by subjecting the compound ofthe formula: ##STR51## wherein all the symbols are the same meaning ashereinbefore defined; and the compound of the formula:

    φ.sub.3 P.sup.+ --R.sup.102 --COOH·X.sup.40.spsp.-(VI)

wherein X⁴⁰ is halogen, φ is phenyl, R¹⁰² is the same meaning ashereinbefore defined;

to wittig reaction.

Wittig reaction is known, for example, it may be carried out by reactingthe phosphonium salt mentioned above in an inert organic solvent (e.g.toluene, THF, dimethylsulfoxide (DMSO) etc.), in the presence of astrong base (e.g. potassium tert-butoxide, lithium diisopropylamide,sodium hydroxide etc.), at -78° C. to room temperature.

The compounds of the formula (V) may be prepared by using a reactiondepicted in following Scheme (B).

The reaction step in parenthesis may be carded out, it desired.

The symbols in scheme is the following meaning or the same meaning ashereinbefore defined.

    ______________________________________                                               X.sup.50 :  halogen,                                                          Me:         methyl,                                                           Et.sub.3 N: triethylamine,                                                    n-BuLi:     n-butyl lithium                                            ______________________________________                                         ##STR52##

As mentioned above, the compounds of the present invention containvarious optical isomers due to asymmetric carbon(s) thereof. However,when a single or a specific optically active substance is desired, itmay be prepared by using a compound having the desired optical activityas a starting material, or by resolving into each optically activesubstance at a preferable step by means such as optical resolution etc.

Starting Materials and Reagents

The starting materials and reagents in the present invention are knownper se or may be prepared by known methods.

For example, the compound which ##STR53## in the compounds of theformula (IV) is described in specification of the U.S. Pat. No.4,861,913 and the U.S. Pat. No. 5,168,101.

Pharmacological Activities

The compounds of the present invention of the formula (Ix) and (Iy) areuseful for PGE₂ antagonists or agonists, because they bind ontoprostaglandin E₂ receptor and have an activity of antagonist or agonistagainst the action thereof. PGE₂ antagonists are expected to inhibit anuterine contraction, to have an analgetic action, to inhibit digestiveperistalsis, to induce sleep. PGE₂ agonists are expected to have uterinecontractile activity, to promote digestive peristalsis, to suppressgastric acid secretion, to lower blood pressure.

For example, in standard laboratory test, the effects were confirmed by(i) the Inhibitory effects of [³ H]-PGE₂ receptor binding in rat uterusmembrane fraction, (ii) the inhibitory effects of rat uterinecontraction induced by PGE₂.

The results of the experiments are shown in the table I and table II.

(i) The measurement of the inhibition of [³ H]-PGE₂ receptor binding

The standard assay mixture contained 5 nM [³ H]-PGE₂ (50 μl), testcompounds (50 μl) and crude membrane fraction obtained from rat uterus(1.2 mg protein/ml, 100 μl) in a final volume of 200 μl (10 mM potassiumphosphate pH 6.0, 0.1M NaCl (buffer A)). After incubation for 1 hour atroom temperature, the reaction was stopped by the addition of 3 ml ofice-cold buffer A, after which the mixture was rapidly filtered througha Whatman GF/B glass filter. The radioactivity associated with thefilter was measured in ACS II (Amarsham) by liquid scintillationcounting. Percent inhibition of specific [³ H]-PGE₂ binding or IC₅₀value, the concentration required to compete with ³ H-PGE₂ receptorbinding by 50% were calculated.

                  TABLE I                                                         ______________________________________                                        Inhibitory effects of PGE.sub.2 receptor binding in rat                                                        IC.sub.50                                    Structure               Ex. No.  (μM)                                      ______________________________________                                         ##STR54##              3 (m)    0.0054                                        ##STR55##              3 (n)    0.12                                          ##STR56##              3 (b)    0.57                                          ##STR57##              3 (c)    6.3                                           ##STR58##              3 (j)    5.0                                           ##STR59##              3 (e)    2.6                                           ##STR60##              3 (f)    0.75                                          ##STR61##              2        0.44                                          ##STR62##              3 (d)    0.82                                          ##STR63##              3 (a)    7.6                                           ##STR64##              3 (k)    0.025                                         ##STR65##              3 (l)    0.36                                          ##STR66##              3 (i)    0.09                                          ##STR67##              3 (h)    0.21                                          ##STR68##              3 (g)    0.054                                         ##STR69##              5 (b)    3.4                                           ##STR70##              4        3.4                                           ##STR71##              5 (c)    5.7                                           ##STR72##              U.S. Pat. No. 5168101 1 (p)                                                            6.4                                           ##STR73##              U.S. Pat. No. 5168101 1 (x)                                                            1.6                                           ##STR74##              U.S. Pat. No. 5168101 1 (y)                                                            0.62                                          ##STR75##              U.S. Pat. No. 5168101 1 (cc)                                                           0.39                                          ##STR76##              5 (i)    6.5                                           ##STR77##              U.S. Pat. No. 5168101 1 (aa)                                                           2.0                                           ##STR78##              U.S. Pat. No. 5168101 1 (bb)                                                           0.82                                          ##STR79##              5 (a)    3.6                                           ##STR80##              5 (d)    2.1                                           ##STR81##              U.S. Pat. No. 5168101 1 (a)                                                            0.77                                          ##STR82##              5 (e)    0.06                                          ##STR83##              5 (f)    5.0                                           ##STR84##              U.S. Pat. No. 5168101 1 (t)                                                            1.2                                           ##STR85##              U.S. Pat. No. 5168101 1 (b)                                                            3.5                                           ##STR86##              U.S. Pat. No. 5168101 1 (c)                                                            0.5                                           ##STR87##              U.S. Pat. No. 5168101 1 (l)                                                            2.4                                           ##STR88##              U.S. Pat. No. 5168101 1 (m)                                                            0.5                                           ##STR89##              5 (g)    3.5                                           ##STR90##              5 (h)    0.2                                           ##STR91##              Euro- pean Patent Publica- tion No. 0312906 1                                          1.8                                           ##STR92##              Euro- pean Patent Publica- tion No. 0312906 1                                          8.0                                           ##STR93##              U.S. Pat. No. 5168101 1 (i)                                                            2.4                                          ______________________________________                                    

                                      TABLE II                                    __________________________________________________________________________    Inhibitory effects of PGE.sub.2 receptor binding in rat                       Structure                   Ex. No.                                                                            IC.sub.50 (μM)                            __________________________________________________________________________     ##STR94##                  6 (2)                                                                              0.0036                                        ##STR95##                  6 (14)                                                                             0.8                                           ##STR96##                  6 (12)                                                                             <0.01                                         ##STR97##                  6 (18)                                                                             0.017                                         ##STR98##                  6 (19)                                                                             0.23                                          ##STR99##                  6 (21)                                                                             0.6                                           ##STR100##                 6 (22)                                                                             1.8                                           ##STR101##                 6 (26)                                                                             0.038                                         ##STR102##                 9    0.26                                         __________________________________________________________________________

(ii) The inhibitory effects of compounds on contraction of rat uterusinduced by PGE₂

Pseudo pregnant rat uterus (Sprague Dawley, 200-300 g, induced byoestradiol 500 μl/kg s.c. 18-24 hours before experiment) was isolatedand longitudinal strips of 1-1.5 cm were set up in Locke-Ringer solutioncontaining low Ca²⁺, aerated with mixed gas (oxygen 95%+carbon dioxide5%) at 28° C. A resting tension of 1 g was imposed on the tissue andcontraction were recorded isometrically and displayed on recticorder.

The compound of example 6(12) completely inhibited the contractioninduced by 0.3 μM PGE₂.

Toxicity

The toxicity of the compound of the present invention of the formula(Ix) and (Iy) are very low and therefore, it may be estimated safe forpharmaceutical use.

For example, the acute toxicity (LD₅₀) in mouse of 6-[(1S, 2R, 3R,4R)-3-(4-bromophenylsulfonylaminomethyl)bicyclo[2.2.1]heptan-2-yl]-5Z-hexenoicacid (it is described as example 1(y) in specification of the U.S. Pat.No. 5,168,101.) was more than 300 mg/kg by oral administration.

Application for Pharmaceuticals

The compounds of the present invention of the formula (Ix) and (Iy),cyclodextrin clathrates thereof and non-toxic salts thereof, are usefulfor PGE₂ antagonists or agonists, because they bind onto prostaglandinE₂ receptor and have an activity of antagonist or agonist against theaction thereof.

PGE₂ antagonists are considered to inhibit uterine contraction, to havean analgetic action, to inhibit digestive peristalsis, to induce sleep,therefor they are useful for prevention and/or treatment of abortion,pain, diarrhea, insomnia.

PGE₂ agonists are considered to have uterine contractile activity, topromote digestive peristalsis, to suppress gastric acid secretion, tolower blood pressure, therefor they are useful for prevention and/ortreatment of constipation, ulcer, gastritis, hypertensive, and forinduction of labour in pregnant female mammals.

For the purpose above described, the compounds of the formula (Ix) and(Iy), of the present invention and cyclodextrin clathrates thereof andnon-toxic salts thereof may be normally by administered systemically orpartially usually by oral or parenteral administration.

The doses to be administered is determined depending upon age, bodyweight, symptom, the desired therapeutic effect, the route ofadministration, and the duration of the treatment etc. In the humanadult, the doses per person per dose are generally between 0.01 mg and0.1 mg, by oral administration up to several times per day, and between1 μg and 100 μg, by parenteral administration up to several times perday. As mentioned above, the doses to be used depend upon variousconditions. Therefore, there are cases in which doses lower than orgreater than the ranges specified above may be used.

Solid compositions according to the present invention for oraladministration include compressed tablets, dispersible powders andgranules. In such solid compositions, one or more of the activecompound(s) is or are, admixed with at least one inert diluent such aslactose, mannitol, glucose, hydroxypropylcellulose, microcrystallinecellulose, starch, polyvinylpyrrolidone or magnesium metasilicatealuminate. The compositions may also comprise, as is normal practice,additional substances other than inert diluents e.g. lubricating agentssuch as magnesium stearate, disintegrating agents such as cellulosecalcium glycolate, stabilizing agent e.g. lactose and assistant fordissolving e.g. arginine, glutamic acid or aspartic acid. The tablets orpills may, if desired, be made into gastric film-coated or entericfilm-coated tablets or pills, such as sugar-coated, gelatin-coated,hydroxypropyl cellulose-coated or hydroxypropylmethyl cellulosephthalate-coated tablets or pills; two or more of layers may be used.The compositions for oral administration also include capsules ofabsorbable material such as gelatin.

Liquid compositions for oral administration includepharmaceutically-acceptable emulsions, solutions, suspensions, syrupsand elixirs containing inert diluents commonly used in the art such asdistilled water or ethanol. Besides inert diluents such compositions mayalso comprise adjuvants such as wetting and suspending agents, andsweetening, flavouring, perfuming and preserving agents.

Other compositions for oral administration include spray compositionswhich may be prepared by known methods and which comprise one or more ofthe active compound(s).

Preparations for injection according to the present invention forparenteral administration include sterile aqueous or non-aqueoussolutions, suspensions or emulsions. Example of aqueous solvents orsuspending media are distilled water for injection and physiologicalsalt solution. Examples of non-aqueous solvents or suspending media arepropylene glycol, polyethylene glycol, vegetable oils such as olive oil,alcohols such as ethanol, POLYSORBATE 80 (registered Trade Mark). Thesecompositions may also include adjuvants such as preserving, wetting,emulsifying, dispersing agents, stabilizing agents (e.g. lactose) andassistant agent for dissolving (e.g. arginine, glutamic acid or asparticacid). They may also be manufactured in the form of sterile solidcompositions which can be dissolved in sterile water or some othersterile injectable medium immediately before use.

Other compositions for parenteral administration include liquids forexternal use, and endermic liniments such as ointments, suppositoriesfor rectal administration and pessaries for vaginal administration whichcomprise one or more of the active compound(s) and may be prepared byknown methods.

REFERENCE EXAMPLES AND EXAMPLES

The following reference examples and examples illustrate the presentinvention, but not limit the present invention.

In the reference examples and examples, "TLC", "NMR", "IR" and "MS"represent "Thin layer chromatography", "Nuclear magnetic resonancespectrum", "Infrared absorption spectrum" and "Mass spectrum",respectively.

The solvents in the parentheses show the developing or eluting solventsand the rations of the solvents used are by volume in chromatographicseparations.

Unless otherwise specified, "NMR" was measured in a chloroform-d (CDCl₃)solution and "IR" was measured by the liquid film method respectively.

And (±) in reference examples and examples represent the mixture ofenantiomers having different angles of rotation as generally used in thenomenclature. For example, ##STR103## represents the mixture of##STR104## and * are added to indications of absolute configuration atthe same time.

Example 1

7-[(1S,2S,3S,5R)-3-(4-bromophenyl)sulfonylamino-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid methyl ester ##STR105##

A solution of7-[(1S,2S,3S,5R)-3-amino-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoicacid methyl ester (the compound was described as reference example 14 inspecification of the U.S. Pat. No. 4,792,550.) (140 mg) in pyridine (5ml) was cooled with ice-bath. A solution of 4-bromobenzenesulfonylchloride (153 mg) in methylene chloride (2 ml) was dropped to the abovesolution. The mixture was stirred for 16 hours at room temperature. Thereaction mixture was poured into 4N hydrochloric acid (30 ml) andextracted with ethyl acetate. The extract was washed with saturatedsodium bicarbonate and brine, successively, dried over magnesium sulfateand concentrated under reduced pressure. The residue was purified bycolumn chromatography on silica gel (ethyl acetate: n-hexane=1:6) togive the title compound (155 mg) having the following physical data.

NMR: δ 7.77 (2H, d), 7.64 (2H, d), 5.29 (2H, m), 4.62 (2H, d), 3.70 (3H,s), 3.59 (1H, m), 2.30 (2H, t), 1.18 (3H, s), 0.95 (3H, s), 0.76 (1H,d);

MS: m/e 497 (M⁺), 499, 466, 468, 428, 430, 401, 403, 396, 398.

Example 2

7-[(1S,2S,3S,5R)-3-(4-bromophenyl)sulfonylamino-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid ##STR106##

To a solution of the methyl ester compound prepared in example 1 (60 mg)in methanol (6 ml), 10% sodium hydride solution (2 ml) was added. Themixture was stirred for 5 hours at room temperature. After methanol wasdistilled off from the reaction mixture, ice and 3N hydrochloric acid(20 ml) were added to the residue. The above solution was extracted withethyl acetate (three times). The extract was dried over magnesiumsulfate and concentrated under reduced pressure to give the titlecompound (53 mg) having the following physical data.

TLC: Rf 0.45 (methylene chloride: methanol=10:1);

NMR: δ 7.77 (2H, td), 7.65 (2H, td), 5.50˜5.24 (3H, m), 3.63 (1H, m),2.43˜1.42 (14H), 1.17 (3H, s), 0.94 (3H, s), 0.76 (1H, d);

MS: m/e 483 (M⁺), 465, 414, 396;

Feature: pale yellow amorphous.

Example 3

By the same procedure as in example 1→example 2, using7-[(1S,2S,3S,5R)-3-amino-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoicacid methyl ester (the compound was described as reference example 14 inspecification of the U.S. Pat. No. 4,792,550.) and various sulfonylcompounds as starting material, purposed compounds shown in followingtable were given.

                                      TABLE III                                   __________________________________________________________________________     ##STR107##                                                                   __________________________________________________________________________    Example                                                                       No.  R.sup.2R.sup.3                                                                             Name           TLC (Rf)                                                                            NMR (δ)                                                                              MS (m/e)                                                                           Feature              __________________________________________________________________________    3 (a)                                                                               ##STR108##  7-[(1S,2S,3S,5R)-3-phenyl sulfonylamino-6,6-dimethyl                          bicyclo[3.1.1]heptan-2-yl]- 5Z-heptenoic                                                     0.50 (methylene chloride: methanol =                                          10:1) 7.92(2H, m), 7.55(3H,m), 5.34(3H,                                             m), 3.66(1H,m), 2.40˜1.44(14H                                           ), 1.16(3H, s), 0.94(3H, s),                                                  0.79(1H, d)  405(M.sup.+),                                                                 387,336, 318                                                                       pale yellow wax      3 (b)                                                                               ##STR109##  7-[(1S,2S,3S,5R)-3-(4- ethylphenyl)sulfonylamino- 6,                          6-dimethylbicyclo[3.1.1] heptan-2-yl]-5Z-heptenoic                                           0.50 (methylene chloride: methanol =                                          10:1) 7.80(2H, d), 7.31(2H, d), 5.35(2H,                                            m), 5.16(1H, d), 3.62(1H, m),                                                 2.71(2H, q), 2.35(2H,                                                         t), 2.30˜1.40(13H, m),                                                  1.24(3H, t), 1.16(3H, s),                                                     0.94(3H, s), 0.76(1H,                                                                      433(M.sup.+), 415,                                                            364, 346, 337, 238,                                                           237  pale yellow oil      3 (c)                                                                               ##STR110##  7-[(1S,2S,3S,5R)-3-(4-tert- butylphenyl)sulfonylamino-                        6, 6-dimethylbicyclo[3.1.1] heptan-2-yl]-5Z-heptenoic                         acid           0.50 (methylene chloride: methanol =                                          10:1) 7.80(2H, dt), 7.48(2H, dt),                                                   5.32(2H, m), 5.12(1H, broad),                                                 3.63(1H, broad), 2.35(2H, t),                                                 2.30˜1.40(13H), 1.34(9H, s),                                            1.16(3H, s),  0.94(3H, s),                                                    0.76(1H, d)  461(M.sup.+), 443,                                                            392, 374, 365,                                                                     pale yellow wax      3 (d)                                                                               ##STR111##  7-[(1S,2S,3S,5R)-3-(4-methoxy phenyl)sulfonylamino-6,                         6- dimethylbicyclo[3.1.1]heptan-2- yl]-5Z-heptenoic                           acid           0.50 (mehylene chloride: methanol =                                           10:1) 7.82(2H, dt), 6.96(2H, dt),                                                   5.38(2H, m), 5.00(1H, broad),                                                 3.85(3H, s), 3.58(1H,                                                         m), 2.40˜1.40(14H), 1.16(3H,                                            ), 0.93(3H, s), 0.76(1H,                                                                   435(M.sup.+), 417,                                                            366, 348,                                                                          colorless wax        3 (e)                                                                               ##STR112##  7-[(1S,2S,3S,5R)-3-(4-fluoro phenyl)sulfonylamino-6, 6-                       imethylbicyclo[3.1.1]heptan-2- yl]-5Z-heptenoic                                              0.45 (mehylene chloride: methanol =                                           10:1) 7.92(2H, dd), 7.18(2H, t),                                                    5.38(3H, m), 3.62(1H, broad),                                                 2.42˜1.40(14H), 1.18(3H, s),                                            0.95(3H, s), 0.76(1H,                                                                      423(M.sup.+), 405,                                                            354, 336                                                                           colorless wax        3 (f)                                                                               ##STR113##  7-[(1S,2S,3S,5R)-3-(4-chloro phenyl)sulfonylamino-6, 6-                       imethylbicyclo[3.1.1]heptan-2- yl]-5Z-heptenoic                                              0.45 (mehylene chloride: methanol =                                           10:1) 7.84(2H, dt), 7.48(2H, dt),                                                   5.40(3H, m), 3.62(1H, broad),                                                 2.42˜1.40(14H), 1.18(3H, s),                                            0.95(3H, s), 0.76(1H,                                                                      439(M.sup.+), 421,                                                            398, 370, 352,                                                                     pale yellow wax      3 (g)                                                                               ##STR114##  7-[(1S,2S,3S,5R)-3-(4- iodophenyl)sulfonylamino- 6,                           6-dimethylbicyclo[3.1.1] heptan-2-yl]-5Z-heptenoic                                           0.45 (methylene cloride: methanol =                                           10:1) 7.85(2H, dt), 7.60(2H, dt),                                                   5.35(2H, m), 5.23(1H, d), 3.61(1H,                                            m), 2.40˜1.40(14H), 1.16(3H,                                            s), 0.93(3H, s), 0.76(1H,                                                                  531(M.sup.+), 513,                                                            463, 444,                                                                          white solid          3 (h)                                                                               ##STR115##  7-[(1S,2S,3S,5R)-3-(4- nitrophenyl)sulfonylamino- 6,                          6-dimethylbicyclo[3.1.1] heptan-2-yl]-5Z-heptenoic                                           0.40 (methylene cloride: methanol =                                           10:1) 8.34(2H, dt), 8.08(2H, dt),                                                   5.49(1H, d), 5.36(2H, m), 3.79(1H,                                            m), 2.40˜1.40(14H), 1.08(3H,                                            ), 0.94(3H, s), 0.76(1H,                                                                   450(M.sup.+), 432,                                                            331, 363                                                                           white wax            3 (i)                                                                               ##STR116##  7-[(1S,2S,3S,5R)-3-(2- naphtyl)sulfonylamino-6, 6-                            dimethylbicyclo[3.1.1]heptan- 2-yl]-5Z-heptenoic                                             0.55 (methylene cloride: methanol =                                           10:1) 8.46(1H, d), 7.92(4H, m), 7.62(2H,                                            m), 5.30(3H, m), 3.68(1H, m),                                                 2.40˜1.44(14H),  1.14(3H,                                               s), 0.92(3H, s), 0.78(1H,                                                                  455(M.sup.+), 437,                                                            414, 386, 368,                                                                     white solid          3 (j)                                                                              (CH.sub.2).sub.3 CH.sub.3                                                                  7-[(1S,2S,3S,5R)-3-butyl                                                                     0.50  5.42(2H, m), 5.00(1H,                                                                      385(M.sup.+),                                                                      pale                                   sulfonylamino-6, 6-dimethyl                                                                  (methylene                                                                          broad), 3.72(1H,                                                                           367,                                                                               yellow                                 bicyclo[3.1.1]heptan-2-yl]-                                                                  chloride:                                                                           3.01(2H, dt),                                                                              298  oil                                    5Z-heptenoic acid                                                                            methanol =                                                                          2.70˜1.35(18H),                                                   10:1) 1.21(3H, s), 1.02(3H, s),                                                     0.94(3H, t), 0.83(1H, d)               3 (k)                                                                              (CH.sub.2).sub.5 CH.sub.3                                                                  7-[(1S,2S,3S,5R)-3-hexyl                                                                     0.45  5.46(2H, m), 4.94(1H,                                                                      413(M.sup.+),                                                                      pale                                   sulfonylamino-6, 6-dimethyl                                                                  (methylene                                                                          3.72(1H, m), 3.02(2H,                                                                      395,                                                                               yellow                                 bicyclo[3.1.1]heptan-2-yl]-                                                                  chloride:          326  oil                                    5Z-heptenoic acid                                                                            methanol =                                                                    10:1)                                        3 (l)                                                                              (CH.sub.2).sub.7 CH.sub.3                                                                  7-[(1S,2S,3S,5R)-3-octyl                                                                     0.45  5.42(2H, m), 3.72(1H,                                                                      441(M.sup.+),                                                                      pale                                   sulfonylamino-6, 6-dimethyl                                                                  (methylene                                                                          3.00(2H, m)  423,                                                                               yellow                                 bicyclo[3.1.1]heptan-2-yl]-                                                                  chloride:          354  oil                                    5Z-heptenoic acid                                                                            methanol =                                                                    10:1)                                        __________________________________________________________________________    Example                                                                       No.    R.sup.2R.sup.3 Name                    TLC (Rf) IR                     __________________________________________________________________________                                                           (ν cm.sup.-1)       3 (m)                                                                                 ##STR117##    7-[(1S,2S,3S,5R)-3-(2-phenylethyl)sulfonyl amino-6,                           6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z- heptenoic                            acid                    0.24 (ethyl acetate: hexane                                                   = 1:1)   3272, 1708, 1604,                                                             1455, 1306, 1236,                                                             1147, 1062             3 (n)                                                                                 ##STR118##    7-[(1S,2S,3S,5R)-3-(2-cyclohexylethyl)sulfonyl                                amino-6, 6-dimethylbicyclo[3.1.1]heptan-2- yl]-5Z-he                          ptenoic acid            0.25 (ethyl acetate: hexane                                                   = 2:3)   3271, 2926, 1708,                                                             1450, 1309             __________________________________________________________________________

Example 4

7-[(1R,2S,3S,4S)-3-tosylaminobicyclo[2.2.1]heptan-2-yl]-5Z-heptenoicacid ##STR119##

Potassium tert-butoxide (740 mg) was added to a suspension4-carboxybutyltriphenylphosphonium bromide (1.33 g) in toluene (10 ml).The mixture was stirred for 40 minutes at 80° C. The reaction solutionwas cooled at 0° C. A solution of[(1R,2S,3S,4S)-3-tosylaminobicyclo[2.2.1]heptan-2-yl]acetaldehyde (thecompound was described as reference example 20 in specification of theU.S. Pat. No. 5,168,101) (270 mg) in toluene (10 ml) was dropped to thereaction solution. The mixture was stirred for 15 minutes at 0° C. Thereaction mixture was poured into ice-water and extracted with ether. Thewater layer was acidified by adding IN hydrochloric acid (10 ml) andextracted with ethyl acetate. The extract was dried over magnesiumsulfate and concentrated under reduced pressure. The residue waspurified by column chromatography on silica gel (methylenechloride:methanol=25:1) to give the title compound (222 mg) having thefollowing physical data.

TLC: Rf 0.45 (methylene chloride:methanol=10:1);

NMR: δ 7.75(2H, d), 7.28(2H, d), 5.26(2H, m), 5.11(1H, d), 3.00(1H),2.42(3H, s), 2.37(2H, t), 2.16˜0.87(15H);

MS: m/e 391 (M⁺), 373;

Feature: white powder.

Example 5

By the same procedure as in example 4, using corresponding startingmaterials and various phosphonium salts, purposed compounds shown infollowing table IV and table V were given.

                                      TABLE IV                                    __________________________________________________________________________     ##STR120##                                                                   Example No.                                                                         ##STR121##                                                                             Name          TLC (Rf)                                                                            NMR (δ)                                                                             MS (m/e)                                                                           Feature                   __________________________________________________________________________    5 (a)                                                                               ##STR122##                                                                             7-[(2S*,3S*)-3-tosylamino bicyclo[2.2.2]octan-2-yl]-5Z-                       heptenoic acid                                                                              0.45 (methylene chloride: methanol =                                                7.75(2H, d), 7.26(2H, d), 5.28(3H, m),                                        2.86(1H, t), 2.42(3H, s), 2.37(2H, t),                                        .20˜1.10(17H)                                                                       405(M.sup.+), 387,                                                                 white wax                 5 (b)                                                                               ##STR123##                                                                             a mixture of 7-[(1R,2S,3S, 4S)-3-tosylaminobicyclo[2.2.1]                     heptan-2-yl]-5Z-heptenoic acid and an isomer of (1S,                          2S,3S,4R)     0.45 (methylene chloride: methanol =                                                7.74(2H, d), 7.28(2H, d), 5.28(2H, m),                                        5.15(1H, d), 3.00(1H, m), 2.43(3H, s),                                        .35(2H, t), 2.16˜0.87(15H)                                                          391(M.sup.+), 373, 363,                                                       345, 289                                                                           colorless oil             __________________________________________________________________________

                                      TABLE V                                     __________________________________________________________________________     ##STR124##                                                                    ##STR125##                                                                         ##STR126##                                                                                          ##STR127##                                                                                      ##STR128##                                                                             ##STR129##             __________________________________________________________________________    5 (c)                                                                               ##STR130##           7-[(1R*,2S*,3S*,4S*)-3-tosylamino bicyclo[2.2.1                               ]heptan-2-yl]-5Z-heptenoic acid                                                                 0.45 (methylene chloride:meth                                                 anol = 10:1)                                                                           3270, 2950, 1705,                                                             1600, 1420, 1320,                                                             1150, 1090, 815         5 (d)                                                                               ##STR131##           7-[(2S,3S)-3-tosylaminobicyclo[2.2.2] octan-2-y                               l]-5Z-heptenoic acid                                                                            0.50 (methylene                                                               chloride:methanol                                                                      (solution of                                                                  chloroform) 3270,                                                             2950, 1720, 1420,                                                             1330, 1170, 1105        5 (e)                                                                               ##STR132##           7-[2-(4-bromophenylsulfonylamino) cyclohexyl]-5                               Z-heptenoic acid  0.42 (methylene chloride:meth                                                 anol = 9:1)                                                                            (KBr disk method)                                                             3280, 2920, 1690,                                                             1430, 1330, 1155,                                                             1080, 1065              5 (f)                                                                               ##STR133##           7-[2-(4-bromophenylsulfonylamino) cyclohexyl]-5                               Z-heptenoic acid  0.42 (methylene                                                               chloride:methanol                                                                      (KBr disk method)                                                             3280, 2920, 1690,                                                             1430, 1330, 1155,                                                             1080, 1065              5 (g)                                                                               ##STR134##           7-[(1R*,2S*)-2-tosylaminocyclopentyl- 5Z-hepten                               oic acid          0.20 (ethyl acetate: hexane                                                   = 1:1)   3260, 2940, 1705,                                                             1600, 1430, 1320,                                                             1155, 1095, 910         5 (h)                                                                               ##STR135##           7-[(1R*,2S*)-2-(4-bromophenylsulfonyl amino)cyc                               lopentyl]-5Z-heptenoic acid                                                                     0.20 (ethyl acetate: hexane                                                   = 1:1)   (KBr disk method)                                                             3260, 2940, 1690,                                                             1570, 1430, 1380,                                                             1330, 1155, 1090,                                                             1005,                   __________________________________________________________________________                                                          905                     Example                                                                       No.  Stracture             Name              TLC (Rf) IR                      __________________________________________________________________________                                                          (ν cm.sup.-1)        5 (i)                                                                               ##STR136##           6-[(1S,2S,3S,4R)-3-(4-bromophenyl sulfonylamino                               methyl)bicyclo[2.2.1] heptan-2-yl]-5Z-hexenoic                                acid              0.44 (ethyl acetate: hexane                                                   = 1:1)   (KBr disk method)                                                             3260, 2920, 1680,                                                             1310,                   __________________________________________________________________________                                                          1140                

Reference Example 1

Synthesis of (1S,2S,3S,5R)-3-mesylamino-2-[2-(2-tetrahydropyranyloxy)ethyl]-6,6-dimethylbicyclo[3.1.1]heptane ##STR137##

Triethylamine (1.9 ml) was added to a solution of(1S,2S,3S,5R)-3-amino-2-[2-(2-tetrahydropyranyloxy)ethyl]-6,6-dimethylbicyclo[3.1.1]heptane(3.25 g) in methylene chloride (30 ml). The reaction solution wascooled. To the above solution, mesyl chloride (1.0 ml) was droppedslowly. The reaction solution was allowed to stand for 1 hour. Thereaction solution was extracted with methylene chloride. The organiclayer was washed with brine, dried over magnesium sulfate andconcentrated under reduced pressure. The residue was purified by columnchromatography on silica gel (hexane-ethyl acetate) to give the titlecompound (3.05 g) having the following physical data.

TLC: Rf 0.50 (hexane:ethyl acetate=2:1);

MS: m/e 346, 277, 268, 262.

Reference Example 2

Synthesis of (1S,2S,3S,5R)-3-[2-(4-chlorophenyl)-2-hydroxyethylsulfonylamino]-2-[2-(2-tetrahydropyranyloxy)ethyl]-6,6-dimethylbicyclo[3.1.1]heptane##STR138##

The compound prepared in reference example 1 (72.1 mg) was dissolvedinto the mixture of ether (1 ml) and tetramethylethylenediamine (0.22ml) in dried container. A solution of n-butyl lithium in n-hexane(1.62M, 0.45 ml) was added slowly to the reaction solution at roomtemperature. The reaction solution was stirred for 2 hours. A solutionof 4-chlorobenzaldehyde (68.8 mg) in ether (1 ml) was added to the abovesolution. The mixture was stirred for 30 minutes. A saturated aqueoussolution of ammonium chloride was added to the reaction solution. Themixture was allowed to stand for 5 minutes and extracted with a mixturesolvent of n-hexane-ethyl acetate (1:1). The organic layer was washedwith brine, dried over magnesium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography on silicagel (hexane-ethyl acetate) to give the title compound (82 mg) having thefollowing physical data.

TLC: Rf 0.60 (hexane:ethyl acetate=3:2);

MS: m/e 400, 382, 332, 305.

Reference Example 3

Synthesis of(1S,2S,3S,5R)-3-[2-(4-chlorophenyl)vinylsulfonylamino]-2-[2-(2-tetrahydropyranyloxy)ethyl]-6,6-dimethylbicyclo[3.1.1]heptane##STR139##

A mixture of the solution of the compound prepared in reference example2 (258 mg) in methylene chloride (5 ml) and triethylamine (0.25 ml) wascooled. Mesyl chloride was dropped slowly to the above mixture,.Ice-bath was removed. The mixture was stirred for 30 minutes. Water wasadded to the reaction solution. The above solution was extracted withmethylene chloride. The organic layer was washed with brine, dried overmagnesium sulfate and concentrated under reduced pressure. The residuewas purified by column chromatography on silica gel (hexane ethylacetate) to give the title compound (232 mg).

Reference Example 4

Synthesis of(1S,2S,3S,5R)-3-[2-(4-chlorophenyl)vinylsulfonylamino]-2-(2-hydroxyethyl)-6,6-dimethylbicyclo[3.1.1]heptane##STR140##

p-Toluenesulfonic acid (10 mg) was added to a solution of the compoundprepared in reference example 3 (232 mg) in methanol (1.5 ml). Themixture was stirred for 1 hour at room temperature. Triethylamine wasadded to the reaction solution. The mixture was concentrated underreduced pressure. The residue was purified by column chromatography onsilica gel (hexane-ethyl acetate) to give the title compound (187 mg)having the following physical data.

TLC: Rf 0.25 (hexane:ethyl acetate=3:2);

MS: m/e 384, 368, 314, 298, 270.

Reference Example 5

Synthesis of(1S,2S,3S,5R)-3-[2-(4-chlorophenyl)vinylsulfonylamino]-2-formylmethyl-6,6-dimethylbicyclo[3.1.1]heptane##STR141##

A solution of oxalyl chloride (0.07 ml) in methylene chloride (2 ml) wascooled at -70° C. To the above solution, a solution of DMSO (0.07 ml) inmethylene chloride (2 ml) was dropped. The mixture was stirred for 10minutes. A solution of the compound prepared in reference example 4 inmethylene chloride (1 ml) was added to the reaction solution at sametemperature. The mixture was stirred for 30 minutes. Triethylamine (0.25ml) was added to the reaction solution. Dry ice-bath was removed. Themixture was stirred for 30 minutes and extracted with ether. The organiclayer was washed with water and brine, dried over magnesium sulfate andconcentrated under reduced pressure to give the title compound.

Example 6

Synthesis of7-[(1S,2S,3S,5R)-3-[2-(4-chlorophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoicacid ##STR142##

4-carboxybutyltriphenylphosphonium bromide (343 mg) and potassiumt-butoxide (177 mg) was dissolved into THF (5 ml). The mixture wasstirred for 10 minutes. A solution of the compound prepared in referenceexample 5 (113 mg) in THF (3 ml) was dropped to the reaction solution.The mixture was stirred for 1 hour. Water was added to the abovemixture. The mixture solvent of ether-hexane (1:1) was added to thereaction solution. The above solution was separated. The water layer wasacidified by adding 1N hydrochloride. The mixture was extracted withethyl acetate. The organic layer was washed with brine, dried overmagnesium sulfate and concentrated under reduced pressure. The residuewas purified by column chromatography on silica gel (hexane-ethylacetate) to give the title compound (105 mg) having the followingphysical data.

TLC: Rf 0.25 (hexane:ethyl acetate=1:1);

MS: m/e 465, 447, 396, 378;

IR: ν3271, 2922, 1708, 1309, 1144 cm⁻¹.

Example 6(1)˜6(26)

By the same procedure as in reference example 1˜5 and example 6, usingcorresponding starting materials and corresponding phosphonium slats,the title compound having the physical data shown in table VI, VII andVIII were given.

                                      TABLE VI                                    __________________________________________________________________________     ##STR143##                                                                   Example                                                                       No.   (R.sup.Y)x                                                                          Name                 TLC (Rf)  IR (ν cm.sup.-1)                __________________________________________________________________________    6 (1) 3-F   7-[(1S, 2S, 3S, 5R)-3-[2-(3-fluorophenyl)                                                          0.25      3271, 2922, 1709,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1584, 1447, 1142                               [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:1)                        6 (2) 4-F   7-[(1S, 2S, 3S, 5R)-3-[2-(4-fluorophenyl)                                                          0.30      3272, 2922, 1709,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1602, 1510, 1143                               [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:1)                        6 (3) 4-Br  7-[(1S, 2S, 3S, 5R)-3-[2-(4-bromophenyl)                                                           0.20      3272, 2917, 1708                               vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl                                                   [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:1)                        6 (4) 4-CH.sub.3 O                                                                        7-[(1S, 2S, 3S, 5R)-3-[2-(4-methoxyphenyl)                                                         0.30      3272, 2921, 1708,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1423, 1259                                     [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:1)                        6 (5) 4-CH.sub.3                                                                          7-[(1S, 2S, 3S, 5R)-3-[2-(4-methylphenyl)                                                          0.20      3272, 2918, 1708,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1441, 1142                                     [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:1)                        6 (6) 3-CH.sub.3 O                                                                        7-[(1S, 2S, 3S, 5R)-3-[2-(3-methoxyphenyl)                                                         0.21      3272, 2921, 1708,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1580, 1434, 1142                               [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:1)                        6 (7) 3-Br  7-[(1S, 2S, 3S, 5R)-3-[2-(3-bromophenyl)                                                           0.25      3272, 2921, 1708,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1439, 1143                                     [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:1)                        6 (8) 2,6-diCH.sub.3                                                                      7-[(1S, 2S, 3S, 5R)-3-[2-(2,6-dimethylphenyl)                                                      0.36      3271, 2922, 1709,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1441, 1307, 1142                               [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:1)                        6 (9) 3-CH.sub.3                                                                          7-[(1S, 2S, 3S, 5R)-3-[2-(3-methylphenyl)                                                          0.30      3272, 2922, 1708,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1440, 1331, 1141                               [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:2)                        6 (10)                                                                              3-Cl  7-[(1S, 2S, 3S, 5R)-3-[2-(3-chlorophenyl)                                                          0.35      3272, 2922, 1708,                              vinylsulfonylamino]-6,6-dimethylbicyclo                                                            (ethyl    1432, 1332, 1143                               [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                              acetate:hexane = 1:2)                        6 (11)                                                                              3-CF.sub.3                                                                          7-[(1S, 2S, 3S, 5R)-3-[2-(3-trifluoromethyl                                                        0.30      3280, 2925, 1709,                              phenyl)vinylsulfonylamino]-6,6-dimethyl                                                            (ethyl    1440, 1333, 1133                               bicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid                                                       acetate:hexane = 2:3)                        6 (12)                                                                              H     7-[(1S, 2S, 3S, 5R)-3-(2-phenylvinylsulfonyl                                                       0.30      3339, 2929, 1679,                              amino)-6,6-dimethylbicyclo[3.1.1]heptan-2-                                                         (ethyl    1453, 1302, 1142                               yl]-5Z-heptenoic acid                                                                              acetate:hexane = 1:2)                        __________________________________________________________________________

                                      TABLE VII                                   __________________________________________________________________________     ##STR144##                                                                   __________________________________________________________________________    Example                                                                       No.    R.sup.x  Name                      TLC (Rf)    IR                      __________________________________________________________________________                                                          (ν cm.sup.-1)        6 (13)                                                                                ##STR145##                                                                            7-[(1S, 2S, 3S, 5R)-3-(2-cyclohexylvinylsulfonylamino)-                       6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic                                                     0.25 (ethyl acetate:hexane =                                                  2:3)        3271, 2927, 1709,                                                             1450, 1337, 1145        6 (14) C.sub.4 H.sub.9                                                                        7-[(1S, 2S, 3S, 5R)-3-(5E-hexenylsulfonylamino)-6,6-                                                    0.30        3339, 2929, 1679,                       dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic                                                         (ethyl      1453, 1302, 1142                                                  acetate:hexane                      __________________________________________________________________________                                              = 1:2)                              Example                                                                       No.  Stracture              Name            TLC (Rf)  IR                      __________________________________________________________________________                                                          (ν cm.sup.-1)        6 (15)                                                                              ##STR146##            7-[(1S, 2S, 3S, 5R)-3-(2-phenylvinyl sulfonyl-                                N-methylamino)-6,6-di- methyl                                                 bicyclo[3.1.1]heptan-2-yl]- 5Z-heptenoic                                                      0.24 (ethyl acetate:hexane =                                                  1:1       1708, 1616, 1577,                                                             1450, 1336, 1142,                                                             973                     6 (16)                                                                              ##STR147##            7-[(1S, 2S, 3S, 5R)-3-(2-phenylvinyl sulfonyla                                mino)-6,6-dimethylbicyclo [3.1.1]heptan-2-yl]-                                4Z-heptenoic acid                                                                             0.21 (ethyl acetate:hexane =                                                  1:1       3271, 1713, 1624,                                                             1577, 1449, 1317,                                                             1142, 1059, 972         6 (26)                                                                              ##STR148##            7-[(1S, 2S, 3S, 5R)-3-(2-phenylvinyl sulfonyla                                mino)-6,6-dimethylbicyclo [3.1.1]heptan-2-yl]-                                5E-heptenoic acid                                                                             0.13 (ethyl acetate:hexane =                                                  1:1       (KBr disk method)                                                             3273, 2921, 1708,                                                             1450, 1328,             __________________________________________________________________________                                                          1143                

                                      TABLE VIII                                  __________________________________________________________________________     ##STR149##                                                                   Example No.                                                                         ##STR150##            Name             TLC (Rf)  IR                     __________________________________________________________________________                                                           (ν cm.sup.-1)       6 (17)                                                                              ##STR151##            7-[(1R, 2S, 3S, 4S)-3-(2-phenylvinyl sulfonyla                                mino)bicyclo[2.2.1]heptan- 2-yl]-5Z-heptenoic                                 acid             0.24 (ethyl acetate:hexane =                                                  1:1)      3274, 1708, 1624                                                              1577, 1450, 1318,                                                             1146, 973              6 (18)                                                                              ##STR152##            6-[(1S, 2S, 3R, 4R)-3-(2-phenylvinyl sulfonyla                                minomethyl)bicyclo[2.2.1] heptan-2-yl]-5Z-hexe                                noic acid        0.13 (ethyl acetate:hexane =                                                  1:1)      3274, 1708, 1623,                                                             1577, 1450, 1418,                                                             1320, 1147, 972        6 (19)                                                                              ##STR153##            7-[(1R*, 2S*)-2-(2-phenylvinylsulfonyl                                        amino)cyclohexyl]-5Z-heptenoic                                                                 0.20 (ethyl acetate:hexane =                                                  1:1)      3272, 1708, 1624,                                                             1577, 1496, 1449,                                                             1319, 1241, 1195,                                                             1148, 1071, 971        6 (20)                                                                              ##STR154##            7-[(1S*, 2S*)-2-(2-phenylvinylsulfonyl                                        amino)cyclohexyl]-5Z-heptenoic                                                                 0.17 (ethyl acetate:hexane =                                                  1:1)      3292, 1708, 1623,                                                             1577, 1451, 1326,                                                             1148, 1005             6 (21)                                                                              ##STR155##            6-[(1R*, 3R*)-3-(2-phenylvinylsulfonyl                                        amino)cyclohexyl]-5Z-hexenoic                                                                  0.30 (ethyl acetate:hexane =                                                  1:1)      3306, 2930, 1708,                                                             1450, 1318, 1146       6 (22)                                                                              ##STR156##            6-[(1S, 3R)-3-(2-phenylvinylsulfonyl-                                         amino)cyclopentyl]-5Z-hexenoic                                                                 0.28 (ethyl acetate:hexane =                                                  1:1)      3307, 2930, 1708,                                                             1451, 1303             6 (23)                                                                              ##STR157##            6-[(1R, 3R)-3-(2-phenylvinylsulfonyl amino)cyc                                lopentyl]-5Z-hexenoic acid                                                                     0.25 (ethyl acetate:hexane =                                                  1:1)      3307, 2990, 1707,                                                             1451, 1317             6 (24)                                                                              ##STR158##            6-[(1S, 3S)-3-(2-phenylvinylsulfonyl amino)cyc                                lopentyl]-5Z-hexenoic acid                                                                     0.25 (ethyl acetate:hexane =                                                  1:1)      3272, 2952, 1708,                                                             1449, 1318, 1145       6 (25)                                                                              ##STR159##            6-[(1R, 3S)-3-(2-phenylvinylsulfonyl amino)cyc                                lopentyl]-5Z-hexenoic acid                                                                     0.28 (ethyl acetate:hexane =                                                  1:1)      3307, 2930, 1708,                                                             1451,                  __________________________________________________________________________                                                           1303               

Example 7

Synthesis of7-[(1S,2S,3S,5R)-3-(2-phenylvinylsulfonylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid methyl ester ##STR160##

To a solution of the compound prepared in example 6(12) (97 mg) inmethanol (5 ml), a solution of diazomethane in ether was added till themixture showed a yellow color at 0° C. The reaction mixture wasconcentrated under reduced pressure. The residue was purified by columnchromatography on silica gel (ethyl acetate-hexane) to give the titlecompound (90 mg) having the following physical data.

TLC: Rf 0.38 (ethyl acetate:hexane=1:2);

IR: ν3274, 1738, 1624, 1577, 1438, 1332, 1146, 1061, 973 cm⁻¹.

Example 8

Synthesis of7-[(1S,2S,3S,5R)-3-(2,2-diphenylvinylsulfonylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoicacid methyl ester ##STR161##

7-[(1S,2S,3S,5R)-3-amino-6,6-dimethylbicyclo[3.1.1]heptan-2yl]-5Z-heptenoicacid methyl ester (The compound was described as reference example 14 inspecification of the U.S. Pat. No. 4,792,550; 145 mg) and triethylamine(0.21 ml) were dissolved into methylene chloride (5 ml) and themixture-was cooled with ice-bath. 2,2-Diphenylvinylsulfonyl chloride(188 mg) was added to the above solution. The mixture was stirred for 2hours at room temperature. The reaction mixture was poured into 1Nhydrochloric acid (5 ml) and extracted with ethyl acetate. The organiclayer was washed with saturated sodium bicarbonate and brine,successively, dried over magnesium sulfate and concentrated underreduced pressure. The residue was purified by column chromatography onsilica gel (3% ethyl acetate/hexane) to give the title compound (203 mg)having the following physical data.

TLC: Rf 0.29 (hexane:ethyl acetate=3:1)

Example 9

Synthesis of7-[(1S,2S,3S,5R)-3-(2,2-diphenylvinylsulfonylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoicacid ##STR162##

To a mixed solution of dimethoxyethane (3 ml) and methanol (1.5 ml) ofthe compound prepared in example 8 (191 mg), 2N sodium hydride solution(1 ml) was added. The mixture was stirred for 4 hours at roomtemperature. After solvent was distilled off the reaction mixture, iceand 1N hydrochloric acid (2 ml) were added to the residue. The abovesolution was extracted with ethyl acetate. The organic layer was washedwith water and brine, successively, dried over magnesium sulfate andconcentrated under reduced pressure. The residue was purified by columnchromatography on silica gel (hexane:ethyl acetate=2:1→1:2 (0.1% aceticacid)) to give the title compound (101 mg) having the following physicaldata.

TLC: Rf 0.21 (hexane:ethyl acetate=1:1);

NMR: δ 7.48-7.22 (10H, m), 6.87 (1H, s), 5.49-5.26 (2H, m), 4.58 (1H,d), 3.73 (1H, m), 2.60-1.84 (10H, m), 1.80-1.47 (4H, m), 1.18 (3H, s),0.98 (3H, s), 0.70 (1H, d).

Formulation Example 1: Preparation of Tablets

The following compounds were admixed in conventional method and punchedout to obtain 100 tablets each containing 100 mg of active ingredient.

    ______________________________________                                        7-[(1S,2S,3S,5R)-3-tosylamino-6,6-dimethylbicyclo                                                        10     g                                           [3.1.1]heptan-2-yl]-5Z-heptenoic acid                                         Cellulose calcium glycolate (disintegrating agent)                                                       200    mg                                          Magnesium stearate (lubricating agent)                                                                   100    mg                                          Micro crystalline cellulose                                                                              9.7    g                                           ______________________________________                                    

Formulation Example 2: Preparation of Tablets

The following compounds were admixed in conventional method and punchedout to obtain 100 tablets each containing 100 mg of active ingredient.

    ______________________________________                                        7-[(1S,2S,3S,5R)-3-[2-(4-chlorophenyl)vinylsulfonylamino]-                                                10     g                                          6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid                      Cellulose calcium glycolate (disintegrating agent)                                                        200    mg                                         Magnesium stearate (lubricating agent)                                                                    100    mg                                         Micro crystalline cellulose 9.7    g                                          ______________________________________                                    

Formulation Example 3: Preparation of Injections

7-[(1S,2S,3S,5R)-3-tosylamino-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoicacid (5 g) and mannitol (50 g) were dissolved by adding distilled water.Then, distilled water was added thereto to make the total volume 500 ml.The solution was filtrated by a bacteria-retaining filter. The solutionwas placed in 5 ml portion in 10 ml vial in usual way and freeze-driedto obtain 100 vials each containing 50 mg of active ingredient.

Formulation Example 4: Preparation of Injections

7-[(1S,2S,3S,5R)-3-[2-(4-chlorophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoicacid (5 g) and mannitol (50 g) were dissolved by adding distilled water.Then, distilled water was added thereto to make the total volume 500 ml.The solution was filtrated by a bacteria-retaining filter. The solutionwas placed in 5 ml portion in 10 ml vial in usual way and freeze-driedto obtain 100 vials each containing 50 mg of active ingredient.

What is claimed is:
 1. Carbocyclic sulfonamides of the formula: ##STR163## R¹⁰⁰ is C4-7 alkylene or C4-7 alkenylene; R²⁰⁰ is hydroxy, C1-20 alkoxy or NR²³⁰ R²⁴⁰ in which R²³⁰ and R²⁴⁰ each, independently, is hydrogen, C1-4 alkyl or NR²³⁰ R²⁴⁰ is amino acid residue;R³⁰⁰ is a single bond or C1-4 alkylene; R⁴⁰⁰ is hydrogen or C1-4 alkyl; R⁵⁰⁰ and R⁹⁰⁰ each, independently, is ##STR164## in which R⁶⁰⁰ is hydrogen, C1-4 alkyl, C1-4 alkoxy, hydroxy, halogen, trifluoromethyl, nitro; nn is 1, 2 or 3; ##STR165## in which R⁶¹⁰ is hydrogen, C1-4 alkyl, C1-4 alkoxy, hydroxy, halogen, trifluoromethyl, nitro; mm is 1, 2 or 3; ##STR166## in which R⁶²⁰ is hydrogen, C1-4 alkyl, C1-4 alkoxy, hydroxy, halogen, trifluoromethyl, nitro; kk is 1, 2 or 3; pp is 3, 4, 5, or 6;iv) C1-7 alkyl or v) hydrogen; cyclodextrin clathrates thereof or non-toxic salts thereof.
 2. A compound according to claim 1, wherein ##STR167##
 3. A compound according to claim 1, wherein ##STR168##
 4. A compound according to claim 1, wherein ##STR169##
 5. A compound according to claim 1, wherein R¹⁰⁰ is pentenylene or hexenylene, R³⁰⁰ is a single bond or methylene.
 6. A compound according to claim 2, wherein R⁵⁰⁰ is the formula: ##STR170## wherein all the symbols are the same meaning as defined in claim 1, and R⁹⁰⁰ is hydrogen or the formula: ##STR171## wherein all the symbols are the same meaning as defined in claim
 1. 7. A compound according to claim 1, wherein R⁵⁰⁰ is ##STR172## wherein all the symbols are the same meaning as hereinbefore defined, or C1-7 alkyl and R⁹⁰⁰ is hydrogen.
 8. A compound according to claim 1, which is7-[3-[2-(4-chlorophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid methyl ester, 7-[3-(2-phenylvinylsulfonyl-N-methylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-(2-phenylvinylsulfonylamino)-6,6-dimethyl bicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(3-fluorophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(4-fluorophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(4-bromophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(4-chlorophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(4-metoxyphenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(4-methylphenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(3-metoxyphenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(3-bromophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(2,6-dimethylphenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(3-methylphenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(3-chlorophenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-[2-(3-trifluoromethylphenyl)vinylsulfonylamino]-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-(2-phenylvinylsulfonylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-(2-phenylvinylsulfonylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5E-heptenoic acid, 7-[3-(2,2-diphenylvinylsulfonylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-(2-cyclohexylvinylsulfonylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-(5Z-hexenylsulfonylamino)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-(2-phenylvinylsulfonylamino)bicyclo[2.2.1]heptan-2-yl]-5Z-heptenoic acid, 7-[3-(2-phenylvinylsulfonylaminomethyl)bicyclo[2.2.1]heptan-2-yl]-5Z-hexenoic acid or 7-[2-(2-phenylvinylsulfonylamino)cyclohexyl]-5Z-heptenoic acid.
 9. A compound according to claim 1, wherein ##STR173##
 10. A compound according to claim 1, wherein ##STR174##
 11. A compound according to claim 1, wherein R¹⁰⁰ is pentenylene, R³⁰⁰ is a single bond, R⁵⁰⁰ is ##STR175## wherein all the symbols are the same meaning as defined in claim 1, and R⁹⁰⁰ is hydrogen.
 12. A compound according to claim 1, which is6-[3-(2-phenylvinylsulfonylamino)cyclohexyl]-5Z-hexenoic acid or 6-[3-(2-phenylvinylsulfonylamino)cyclopentyl]-5Z-hexenoic acid.
 13. A pharmaceutical composition for the treatment of abortion, pain, diarrhea, ansomnia, constipation, ulcer, gastritis or hypertension, or for induction of labor in pregnant female mammals, which comprises, as active ingredient, an effective amount of a carbocyclic sulfonamides of the formula (Iy) depicted in claim 1 or cyclodextrin clathrates thereof or non-toxic salts thereof, with a pharmaceutical carrier or coating.
 14. The compound according to claim 2, wherein ##STR176##
 15. The compound according to claim 3, wherein ##STR177##
 16. The compound according to claim 3, wherein ##STR178##
 17. The compound according to claim 4, wherein ##STR179##
 18. The compound according to claim 4, wherein ##STR180##
 19. The compound according to claim 9, wherein ##STR181##
 20. The compound according to claim 10, wherein ##STR182##
 21. The compound according to claim 10, wherein ##STR183##
 22. The compound according to claim 10, wherein ##STR184##
 23. The compound according to claim 10, wherein ##STR185## 